Not a traditional drug phase: Biospecimen Collection for Malignant Solid Neoplasm
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer.
Official registry: https://clinicaltrials.gov/study/NCT04871542 · SWOG Cancer Research Network · enrollment listed as 2,062
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 2,062 people at 849 sites. Taking part typically means a procedure as part of the study plus check-ins.
Official title (unrewritten)
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Interventions: Biospecimen Collection, Questionnaire Administration
Primary outcome (registry wording): Occurrence of severe or worse non-hematological immune-related adverse event (irAE)
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Participants who have received prior ICI-based therapy must have completed ICI based therapy at least 180 days prior to registration
- Participants must not have discontinued any prior ICI-based therapy (if applicable) because of irAE
- Participants must not have received chemotherapy, biologic, or targeted-therapy within 21 days prior to registration
- Participants must have recovered from side effects of prior therapy to the following standards per treating physician's discretion:
- =\< Grade 1 for any non-hematologic side effects (excluding neuropathy and alopecia); lab-related parameters of liver and renal function will be considered at the discretion of the treating physician)
- =\< Grade 2 for neuropathy and/or alopecia
- Grade 3 or less for any hematologic side effects
Who the registry excludes
- People the protocol lists as excluded — the study team must confirm.
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
849 listed- Anchorage Associates in Radiation Medicine — Anchorage, Alaska (recruiting)
- Anchorage Radiation Therapy Center — Anchorage, Alaska (suspended)
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska (recruiting)
- Alaska Oncology and Hematology LLC — Anchorage, Alaska (recruiting)
- Alaska Women's Cancer Care — Anchorage, Alaska (recruiting)
- Anchorage Oncology Centre — Anchorage, Alaska (suspended)
- Katmai Oncology Group — Anchorage, Alaska (recruiting)
- Providence Alaska Medical Center — Anchorage, Alaska (recruiting)
- Fairbanks Memorial Hospital — Fairbanks, Alaska (suspended)
- Kingman Regional Medical Center — Kingman, Arizona (recruiting)
- Cancer Center at Saint Joseph's — Phoenix, Arizona (recruiting)
- Banner University Medical Center - Tucson — Tucson, Arizona (suspended)
+ 6 sites outside the US on the same record
FAQ about this NCT record
Is NCT04871542 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT04871542?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT04871542?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary